1812 Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival. Retrospective analyses of the STO3 randomizedtrial. (September 2015) - Lindström, L.S.; Yau, C.; Czene, K.; Thompson, C.K.; Van't Veer, L.J.; Nordenskjöld, B.; Stål, O.; Fornander, T.; Benz, C.C.; Borowsky, A.D.; Esserman, L.J.